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Summary
Objective The objective of our study was to evaluate the 
prevalence of abnormal maternal echocardiographic 
findings in triplet pregnancies presenting with dyspnoea.
Study design Between 2003 and 2013, patients’ 
records of 96 triplet pregnancies at our department were 
analysed including maternal and fetal outcome, echo-
cardiographic parameters and N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) levels. After exclusion 
of triplet pregnancies with fetal demise before 23 + 0 
weeks, selective feticide or missing outcome data, the 
study population consisted of 60 triplet pregnancies. All 
women with dyspnoea underwent echocardiography 
and measurement of NT-proBNP.
Results Dyspnoea towards the end of pregnancy was 
observed in 13.3 % (8/60) of all women with triplet preg-
nancies, and all of these women underwent echocardiog-
raphy. The prevalence of abnormal echocardiographic 
findings in women with dyspnoea was 37.5 % (3/8) with 
peripartum cardiomyopathy in one woman. Median 
serum NT-proBNP was significantly higher in women 
with abnormal echocardiographic findings compared 
with those without (1779 ng/ml, range 1045–6076 ng/ml 
vs 172  ng/ml, range 50–311  ng/ml; p < 0.001 by Mann-
Whitney-U Test).
Conclusion We conclude that triplet pregnancies 
presenting with dyspnoea show a high prevalence of 
abnormal echocardiographic findings. Since dyspnoea 
is a common sign in triplet pregnancies and is associ-
ated with a high rate of cardiac involvement, echocar-
diography and evaluation of maternal NT-proBNP could 
be considered to improve early diagnosis and perinatal 
management.
Keywords Triplet pregnancy  · Maternal echocardiog-
raphy  · Pro-B-type natriuretic peptide  · Multiple preg-
nancy · Dyspnoea in pregnancy
Introduction
The prevalence of multiple pregnancies has increased 
over the past three decades due to increases in ovulation 
induction, in vitro fertilisation and childbearing at older 
ages [1, 2]. Triplet pregnancies are associated with sig-
nificantly increased risks of maternal and fetal morbidity 
compared to singleton and twin pregnancies [3]. Despite 
advances in neonatal care, no significant improvement 
in the outcome of triplet pregnancies has been reported 
during the past three decades, and almost all triplets are 
born preterm before 34 weeks [4–6].
Women with triplet pregnancies have significantly 
higher frequencies of hypertension, pre-eclampsia and 
diabetes [7]. Furthermore, women carrying triplet preg-
nancies are under particular physical stress because 
already in the second trimester the uterus enlarges to 
a size comparable to that of a singleton at term; there-
fore many women with uncomplicated triplet pregnancy 
report physical discomfort including dyspnoea [8].
Symptoms of reduced cardiac function or heart failure 
may mimic normal physiological findings of late preg-
nancy, including persistent tiredness, oedema, orthop-
noea and dyspnoea on exertion [9].
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One cause of heart failure that affects women late in 
pregnancy or in the early puerperium is peripartum car-
diomyopathy with a reported maternal mortality rate of 
9 % [10]. It is defined as an idiopathic cardiomyopathy 
presenting with heart failure secondary to left ventricu-
lar systolic dysfunction at the end of pregnancy or in the 
months following delivery [9]. Risk factors of peripar-
tum cardiomyopathy include non-Caucasian ethnicity, 
advanced maternal age, multiparity, poor socioeconomic 
status, prolonged tocolytic use (beta-adrenergic ago-
nists), gestational hypertension, pre-eclampsia and mul-
tiple pregnancy [10–12].
N-terminal pro-B-type natriuretic peptide (NT-
proBNP) is secreted from the cardiac ventricles in 
response to ventricular volume expansion and pres-
sure overload [13–15]. Nowadays, it is a well-established 
marker of heart failure, being correlated with systolic 
and diastolic dysfunction, severity of cardiac failure and 
associated symptoms [16]. In 2009, Franz et al. described 
elevated NT-proBNP levels in healthy pregnant women 
compared to non-pregnant women [17], and in 2008 
Forster et al. described elevated levels of NT-proBNP in 
women with peripartum cardiomyopathy [18].
To our knowledge, there are no data about the preva-
lence of peripartum cardiomyopathy or abnormal car-
diac function in women with triplet pregnancies. Thus, 
this study aimed to evaluate the prevalence of abnormal 
echocardiographic findings as well as NT-proBNP levels 
in a large cohort of women with triplet pregnancies.
Materials and methods
This retrospective cohort study aims to evaluate the prev-
alence of abnormal maternal echocardiographic findings 
in triplet pregnancies treated at our tertiary referral cen-
tre as part of routine antenatal care. Ethical approval was 
obtained from the Ethics Committee of the Medical Uni-
versity of Vienna, reference number 1633/2012.
During a study period of 10 years, over 26.000 preg-
nancies were referred to our hospital. Of those, 96 
women (0.38 %) presented with a triplet pregnancy. 
Medical records of all women with triplet pregnancies 
who attended our department between December 2003 
and December 2013 were reviewed. Demographic char-
acteristics and data on pregnancy outcome were col-
lected from the hospital maternity records.
Of all triplet pregnancies, 14.6 % (14/96) were excluded 
because of fetal demise before 23 + 0 weeks, and 20.8 % 
(20/96) were excluded because of selective feticide (elec-
tive determination). Furthermore, 2.1 % (2/96) were 
excluded because of missing outcome data. Finally, the 
study population consisted of 60 women with triplet 
pregnancies.
Women with triplet pregnancies routinely underwent 
ultrasound screening at 11 + 0 to 13 + 6 weeks since first 
trimester screening has been established. Chorionic-
ity and amnionicity were routinely determined at first 
trimester screening by ultrasound examination of the 
dividing membranes characteristics and by examina-
tion of the placenta after birth. At 20–22 weeks, preg-
nant women routinely underwent anatomy scan. From 
16 weeks of gestation onward, triplet pregnancies were 
routinely seen in 2-weekly intervals at our institution’s 
outpatient clinic. All women were seen by operators spe-
cialised in the field of multiple pregnancies. If a woman 
presented with dyspnoea (which was clinically diagnosed 
by an experienced consultant), clinical assessment using 
2-dimensional transthoracic and Doppler echocardiog-
raphy was performed.
All patients’ medical records were reviewed for mater-
nal parameters such as maternal age, body mass index 
(BMI), pre-existing cardiac disease, smoking behaviour, 
parity, method of conception, pregnancy complica-
tions (e.g. hypertension, pre-eclampsia or diabetes), use 
of tocolytics, mode of delivery and neonatal outcome 
parameters such as live birth, gestational age at delivery, 
birth weight, apgar 5 min after birth, arterial cord blood 
pH and admission to the neonatal intensive care unit.
Furthermore, all patients’ medical records were 
reviewed for reports of dyspnoea, maternal echocardio-
graphic ultrasound examinations and maternal serum 
NT-proBNP levels.
The main outcome parameter of this study was the 
prevalence of abnormal maternal echocardiographic 
findings in women with triplet pregnancies.
Furthermore, we evaluated the prevalence of peripar-
tum cardiomyopathy. We used the definition of the Euro-
pean Society of Cardiology Study Group on Peripartum 
Cardiomyopathy for defining peripartum cardiomyopa-
thy: ‘Peripartum cardiomyopathy is an idiopathic car-
diomyopathy presenting with heart failure secondary to 
left ventricular systolic dysfunction towards the end of 
pregnancy or in the months following delivery, where no 
other cause of heart failure is found. It is a diagnosis of 
exclusion. The left ventricle may not be dilated but the 
ejection fraction is nearly always reduced below 45 %’ [9].
Echocardiographic results were analysed according 
to the guidelines of the National Heart, Lung and Blood 
Institute and Office of Rare Diseases (National Institutes 
of Health) Workshop on Peripartum Cardiomyopathy 
including an ejection fraction of 45 % or less, fractional 
shortening of less than 30 %, or both and end-diastolic 
dimension of greater than 2.7 cm/m2 body surface area 
[19].
Statistical analyses were performed with SPSS software 
(version 18.0; SPSS, Chicago, IL). Parametric continuous 
variables were summarised as means (± standard devia-
tion), non-parametric continuous variables as medi-
ans (minimum and maximum) and categorical data as 
percentages. Categorical variables were analysed using 
Fisher’s exact test, continuous variables were compared 
using unpaired T-test, Kruskal-Wallis or Mann-Whitney 
U-test. For infant outcomes, the correlation within sets 
of triplets was accounted for by considering robust esti-
mates of variance based on the method of generalised 
estimating equations (GEE) [20].
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Women with abnormal echocardiographic findings 
are described in detail:
Patient no. 1 was a 30-year-old woman with a dicho-
rionic triamniotic triplet pregnancy and mild pre-
eclampsia from 26 weeks of gestation onwards. As 
antihypertensive therapy she received methyldopa. At 
30.3 weeks of gestation, she presented with dyspnoea 
and oedema. Echocardiography showed normal left ven-
tricular ejection fraction, impaired cardiac relaxation 
and pericardial effusion, and NT-proBNP was 1045  ng/
ml. Maternal infections were excluded. The next day, dys-
pnoea and oedema worsened, additionally the woman 
reported palpitations, and therefore caesarean section 
was performed. Clinical improvement began right after 
delivery, and after 6 days the mother was free of symp-
toms and discharged from hospital.
Patient no. 2 was a 28-year-old woman with a tricho-
rionic triamniotic triplet pregnancy who presented with 
dyspnoea at 33.6 weeks of gestation. Echocardiography 
showed abnormal left ventricular diastolic function 
and impaired cardiac relaxation, and NT-proBNP was 
1779 ng/ml. The next day the woman reported worsened 
dyspnoea, and caesarean section was performed. She 
recovered soon after delivery, and NT-proBNP decreased 
to 372 ng/ml. Five days after delivery the mother was free 
of symptoms and discharged from hospital.
Patient no. 3 was a 37-year-old woman with a tricho-
rionic triamniotic triplet pregnancy with insulin-depen-
dent gestational diabetes. She presented with dyspnoea 
at 31.9 weeks of gestation. Echocardiography showed a 
left ventricular ejection fraction of 50 %. One day later, 
caesarean section was performed due to more pro-
nounced dyspnoea resulting in marked limitation of 
physical activity in accordance with New York Heart 
Association functional class III (The Criteria Commit-
tee of the NYHA, 1994). After delivery, the patient was 
transferred to the Department of Cardiology, and echo-
cardiography showed a reduced left ventricular ejection 
fraction of 36 % and pericardial effusion, and the diagno-
sis of peripartum cardiomyopathy was made. NT-proBNP 
was 6076  ng/ml. Therapy with ramipril and bisoprolol 
was started, and the symptoms got better. Twenty-four 
days after delivery, echocardiography showed a left ven-
tricular ejection fraction of 50 %, abnormal septal move-
ments and mitral insufficiency. The patient felt much 
better and could be discharged. In the following months 
she had several check-ups with mild or no symptoms of 
heart failure reported.
NT-proBNP levels were measured in all women with 
dyspnoea (13.3 %, 8/60) at the time of maternal echocar-
diography. Median NT-proBNP levels were significantly 
higher in women with abnormal echocardiographic 
findings compared with those without (1779  ng/ml, 
range 1045–6076 ng/ml vs 172 ng/ml, range 50–311 ng/
ml; p < 0.001 by Mann-Whitney-U Test).
Neonatal outcome is shown in Table 2. Neonatal out-
come did not significantly differ between women with 
abnormal echocardiographic findings and those without.
Results
Sixty triplet pregnancies were analysed, including 63.3 % 
(38/60) trichorionic and 36.7 % (22/60) dichorionic trip-
let pregnancies. Patients’ characteristics are shown in 
Table 1.
The prevalence of abnormal echocardiographic find-
ings in women with dyspnoea was 37,5 % (3/8), with peri-
partum cardiomyopathy in one woman. The whole study 
population showed a high rate of diabetes (23.3 %; 14/60) 
and hypertension (15 %; 9/60). One of the three women 
with abnormal echocardiographic findings had diabetes 
and one had pre-eclampsia.
Dyspnoea was observed in 13.3 % (8/60) of all women 
with triplet pregnancies, and all of these women under-
went clinical assessment using 2-dimensional transtho-
racic and Doppler echocardiography. Mean gestational 
age at examination was 27.8 (± 4.6) weeks of gestation. 
Three women had abnormal echocardiographic find-
ings (abnormal left ventricular function, pericardial 
effusion). All other women with dyspnoea had normal 
echocardiographic results, and in one woman the previ-
ously described mitral insufficiency was confirmed with-
out worsening.








findings (n = 3)
Maternal age (years; 
mean, SD)
30.8 (± 5.0) 31.0 (± 3.8)
BMI (kg/m2; mean, SD) 24.0 (± 3.5) 25.2 (± 1.1)
Pre-existing cardiac 
disease (n, %)
1 (1.8 %) –
Smoking (n, %) 10 (17.9 %) –
Nulliparity (n, %) 41 (71.9 %) 3 (100 %)
Method of conception 
(n, %)
- ART 52 (100 %)a 3 (100 %)a
Diabetes mellitus (n, %) 13 (22.9 %) 1 (33 %)
Hypertension (n, %) 9 (15.8 %) –
Pre-eclampsia (n, %) 3 (5.3 %) 1 (33 %)
HELLP syndrome (n, %) 1 (1.7 %) –
Use of tocolytics (n, %) 47 (82.5 %) 3 (100 %)
Mode of delivery (n, %)
- Caesarean section 56(98.2 %) 3 (100 %)
- Vaginal delivery 1 (1.8 %) –
Dyspnoea (n, %) 5 (8.8 %)b 3 (100 %)b
GA (wks) at echocardiog-
raphy (median, range)
31.9 (27.0–33.3) 31.9 (30.3–33.6)
SD standard deviation, BMI body mass index, ART assisted reproductive 
technique, GA gestational age, wks weeks, n number
aIn five cases no data about method of conception were available
bp = 0.002 by Fisher’s exact test
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Hypertension and pre-eclampsia have been described 
as risk factors for peripartum cardiomyopathy [10, 11]. 
We observed high rates of hypertension (15 %; 9/60) and 
pre-eclampsia (6.7 %; 4/60) in our population of trip-
let pregnancies, which is in accordance to previously 
reported data [7]. The high prevalence of abnormal echo-
cardiographic findings in our population could partially 
be triggered by the high rate of these complications.
In our study, abnormal echocardiographic findings 
were observed after 30 weeks of gestation. Since triplet 
pregnancies were delivered at a median gestational age 
of 32–34 weeks, reduced cardiac function occurred in the 
last month of pregnancy in our study population, which 
is in accordance with the time of diagnosis of peripartum 
cardiomyopathy in singletons [4, 6].
We showed a prevalence of peripartum cardiomyopathy 
of 1.7 % in triplet pregnancies, which is higher than previ-
ously reported prevalence of 0.1–0.3 % in different popula-
tions including mainly singleton pregnancies [24, 25]. It has 
been suggested that an abnormal maternal immunologic 
response to fetal antigen could lead to peripartum cardio-
myopathy [26]. One could assume that the amount of fetal 
antigen is higher in triplet pregnancies, which could lead to 
a higher prevalence of peripartum cardiomyopathy. How-
ever, available data regarding abnormal immunological 
response in the aetiology of peripartum cardiomyopathy 
are conflicting [18, 26, 27, 28].
It has been described that NT-proBNP, which is a 
quantitative serum marker of cardiac disease reflecting 
systolic and diastolic ventricular dysfunction, is elevated 
in patients with heart failure and in women with peri-
partum cardiomyopathy [29, 30]. Forster et al. described 
elevated levels of NT-proBNP in women with peripartum 
cardiomyopathy [18]. We measured significantly ele-
vated levels of NT-proBNP in all women with abnormal 
echocardiographic findings, with no overlap between 
measurements of women with and without abnormal 
echocardiographic findings.
Although only one woman with abnormal echocardio-
graphic findings fulfilled the diagnostic criteria of peri-
partum cardiomyopathy, one could assume that also the 
other women with abnormal echocardiographic findings 
may have similar pathophysiological processes since 
some shared risk factors for peripartum cardiomyopa-
thy, and all women with abnormal echocardiographic 
findings had significantly elevated levels of NT-proBNP. 
However, this remains speculative.
Since reduced cardiac function can mimic normal 
physiological findings of late pregnancy (dyspnoea, 
exhaustion), and these symptoms are even more pro-
nounced in triplet pregnancies, diagnosis of reduced car-
diac function could be challenging. Nevertheless, 37.5 % 
(3/8) of all women who presented with remarkable dys-
pnoea had abnormal echocardiographic findings, and 
62.5 % (5/8) had normal echocardiographic results.
Triplet pregnancies presenting with dyspnoea show a 
high prevalence of abnormal echocardiographic findings. 
Since dyspnoea is a common sign in triplet pregnancies 
and is associated with a high rate of cardiac involve-
Comment
In our study, we evaluated the prevalence of abnormal 
maternal echocardiographic findings in triplet pregnan-
cies. We could present a high prevalence of abnormal 
echocardiographic findings in women with dyspnoea 
(37.5 %). In one of these (1/3), the diagnosis of peripar-
tum cardiomyopathy was made. Abnormal echocar-
diographic findings were associated with diabetes and 
pre-eclampsia. All women with abnormal echocardio-
graphic findings had markedly elevated NT-proBNP 
levels.
This is one of the largest studies evaluating the preva-
lence of abnormal echocardiographic findings in trip-
let pregnancies. All pregnant women with dyspnoea 
underwent echocardiography. As typical for a retro-
spective study design, our report shows potential limi-
tations. Since we did not perform echocardiography in 
all triplet pregnancies, we could not exclude that even 
women with shortness of breath which seems appro-
priate for pregnancy might have reduced cardiac func-
tion. Nevertheless, in those who presented with more 
pronounced symptoms, the percentage of abnormal 
echocardiographic findings was very high. Furthermore 
NT-proBNP levels were not measured longitudinally and 
not in all women with triplet pregnancies; therefore we 
cannot present normal values for NT-proBNP in triplet 
pregnancies.
The high rate of dyspnoea (13.3 %) in triplet pregnan-
cies could be explained by haemodynamic factors—even 
in singleton pregnancies there is a significant increase in 
blood volume and cardiac output resulting in transient 
left ventricular remodelling and hypertrophy [21–23]. 
This increase may be more pronounced in triplet preg-
nancies and could further lead to higher haemodynamic 
stress and reduced cardiac function with abnormal echo-
cardiographic findings in some triplet pregnancies.




findings (n = 171)
Triplets with abnormal 
maternal echocardiographic 
findings (n = 9)
Live births 167 (97.7 %) 9 (100 %)
GA at delivery 
(weeks; median, 
range)
32.7 (23.3–35.7) 32.0 (30.4–34.0)
Apgar 5 min after 
delivery (median, 
range)
9 (1–10) 9 (7–10)
Arterial cord blood 
pH (median, range)
7.30 (6.95–7.40) 7.10 (7.00-7.28)
Birth weight (g; 
median, range)
1567 (361–2759) 1750 (1280–2400)
NICU (n, %) 157 (94 %) 9 (100 %)
SGA (n, %) 17 (10.1 %) 0
GA gestational age, SD standard deviation, NICU neonatal intensive care 
unit, SGA small for gestational age (< 5th percentile), n number
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